Nov 15 |
Cassava Sciences updates on Phase 3 Alzheimer’s trial ahead of key readout
|
Nov 15 |
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
|
Nov 12 |
What Makes Cassava Sciences (SAVA) a New Buy Stock
|
Nov 11 |
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
|
Nov 8 |
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?
|
Nov 8 |
Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting
|
Nov 7 |
Cassava Sciences: Pivotal Alzheimer's Data May Push Stock Toward Book Value
|
Nov 7 |
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
|
Nov 7 |
Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript
|
Nov 7 |
Cassava Sciences beats in Q3 ahead of key Alzheimer’s readout
|